Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.

Lymph Node Metastases Clinical Trial

Official title:

Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03845647
• Other study ID #: ZDWY.JRWK.002
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2019
• Est. completion date: December 28, 2020

Study information

• Verified date: November 2019
• Source: Fifth Affiliated Hospital, Sun Yat-Sen University
• Contact: Qingan Zeng, doctor
• Phone: 0756-2528810
• Email: zengqa1218[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There are so many contradictions over central lymph node dissection in unilateral cN0(Clinically N0) differentiated thyroid carcinoma.In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0(Clinically N0) differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.

Description:

Being the most common thyroid malignant tumor,differentiated thyroid carcinoma often metastasize to the neck lymph nodes in the early stage,especially to the central lymph node.For management of cervical lymph nodes ,the 2015 American Thyroid Association Management Guidelines suggest that thyroid+Prophylactic unilateral or bilateral central lymph node dissection should be undertaken in the patients with cN0(Clinically N0) progression (T3, T4) and cN1b(Clinically N1b).Chinese guidelines recommend that, in order to avoid operative complications as far as possible (i.e. effective protection of the parathyroid gland and recurrent laryngeal nerve), lymph node dissection in the central area on the same side of the lesion should be performed at least.However, in 2017, the second edition of National Comprehensive Cancer Network(NCCN) thyroid tumor guidelines believed that if lymph nodes in the central region were negative,preventive central region lymph node dissection was not recommended.In conclusion,there are so many contradictions over central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.However,we also can draw a conclusion that it may bring some benefits if bilateral central lymph node dissection were undertaken In some cases.According to researchers' preliminary clinical trials,it is not only that there is a great probability of metastasis in the ipsilateral central lymph nodes , contralateral metastasis is also possible,and even sometimes contralateral central lymph region metastas may occur without ipsilateral central lymph nodes metastasis.In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 28, 2020
• Est. primary completion date: December 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Accurately diagnosing primary differentiated thyroid carcinoma according to pathological diagnostic criteria .

• Differentiated thyroid carcinoma with cN0(Clinically N0) was diagnosed by thyroid ultrasound text and/or neck CT,and was confirmed with differentiated thyroid carcinoma by postoperative pathological examination.

• The age is more than 18 years old and less than 65 years old. There is no gender restriction.

• Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy.

• Physical condition score of Eastern Cooperative Oncology Group(ECOG): 0-2; no major organ dysfunction; oxygen partial pressure = 10.64 kilopascal(kPa); white blood cell count= 4 × 109/ L; hemoglobin= 9.5g/dL; neutrophil absolute count = 1.5 × 109 / L; platelet count = 100× 109 / L; total bilirubin = 1.5 times of the upper limit of normal value;creatinine = 1.25 times of the upper limit of normal value; and creatinine clearance = 60ml / min.

• Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent.

Exclusion Criteria:

• • ?Bilateral DTC(differentiated thyroid cancer) patients ?Non-DTC(differentiated thyroid cancer)patients ? Non-cn0(Clinically N0) patients ? cN0(Clinically N0) patients but could not be operated on.

• Poorly controlled diabetics (fasting blood glucose levels > 200 mg/dL). In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.• Breastfeeding and/or pregnant women.

• Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.).

• Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate.

• People with severe emphysema, pulmonary congestion, and pulmonary heart disease.

• Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).

Related Conditions & MeSH terms

• Carcinoma
• Differentiated Thyroid Carcinoma
• Lymph Node Dissection
• Lymph Node Metastases
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Procedure:
• contralateral central lymph node dissection
contralateral central lymph node dissection

Locations

Country	Name	City	State
China	Fifth Affiliated Hospital, Sun Yat-Sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Fifth Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor diameter	Tumor diameter will be measured by postoperative pathological examination.	12 months
Primary	Number of lymph nodes dissected in every side of central lymph node	Count the number of lymph nodes dissected during operation in every side of central lymph nodes of every Participants.	12 months
Primary	Number of metastatic lymph nodes diagnosed by Postoperative pathology	Count the number of metastatic lymph nodes diagnosed by Postoperative pathology in every side of central lymph nodes of every Participants.	12 months
Secondary	Rate of lymph nodes metastasis	Based on the statistics of Primary Outcome,count the rate of lymph node metastasis.	12 months